Lynda Charters

EyeCon is an opportunity for ophthalmologists and optometrists to sit down together.

The first patients were dosed in the global phase 3 ORBIT trial evaluating linsitinib as an oral therapy for thyroid eye disease.

Q3 2026 delivered advances in some closely watched pipeline products.

Atrial fibrillation appears to cause thinning of the macular ganglion cell and inner plexiform layer.

In patients reporting chronic ocular pain, dry eye may not be the entire diagnosis.

Polish investigators showed that various modalities can quantify ocular changes in attention deficit/hyperactivity disorder.

Opus Genetics announced positive 3- and 6-month results OPGx-BEST1 in BEST1-related retinal diseases.

Startup S5G Therapeutics aims to move ubiquinol technology from the laboratory toward treatments for dry eye, Fuchs dystrophy, and other corneal conditions.

Women are more often affected than men, and the disease manifests differently between the sexes.

Ocugen's global phase 3 ArMaDa3 trial evaluates OCU410, a one-time gene therapy targeting multiple disease pathways in geographic atrophy secondary to dry age-related macular degeneration.

This article discusses the evolution of the body of information about Demodex blepharitis over the years, from the convening of a consensus panel to the realization that a new drug provides rapid relief to the ocular surface.

Researchers from China and Singapore found that the macular microvasculature is altered as early as the pre-diabetic stage of the disease. The findings suggest that the status of the choriocapillaris can be used to monitor early metabolic disease.

Two optical treatment modalities can slow pediatric myopia progression without the need for pharmacologic intervention, ie, spectacle lenses incorporating highly aspherical lenslets (HAL) and orthokeratology (ortho-k) contact lenses. Both treatments are based on the same underlying theory that peripheral retinal defocus is a growth signal for axial elongation‚ but the treatments focus on different structures of the visual system, one through a manufactured spectacle lens surface (HAL) and the other through temporary corneal reshaping (ortho-k).

A new study reported that the so-called “high-pillow sleeping position” can result in elevated intraocular pressure (IOP) values and decreased ocular perfusion pressure (OPP) in patients with glaucoma compared with sleeping in the supine position.

A preclinical study of the effects of aflibercept (Eylea, Regeneron Pharmaceuticals) and faricimab (Vabysmo-svoa, Genentech) showed that the two treatments were equal in their ability to maintain or restore the retinal endothelial barrier function and resultant visual integrity. Investigators attributed this result mainly to inhibiting vascular endothelial growth factor A165 from binding to its receptor.

Alice Epitropoulos, MD, shares cases of Demodex blepharitis and reflects on how lotilaner has changed treatment before ocular surgery.

Topical chloroprocaine hydrochloride ophthalmic gel 3% (IHEEZO, Harrow) resulted in less pain f following intravitreal injections in patients undergoing same-day bilateral intravitreal injections.

The FDA issued a recall notice for an eye drop designed to relieve ocular redness, itching, burning, and watery eyes. The Class II recall alerts consumers and physicians to possible temporary or reversible health effects, but serious harm is unlikely.

Researchers in the UK have developed a new treatment approach for aniridia-related keratopathy (ARK), a rare genetic ocular disease, namely, a collagen scaffold that delivers limbal epithelial stem cells and stromal stem cells to the area affected by ARK. The treatment resulted in improved ocular surface scores and visual acuities.

The Jack McGovern Coats' Disease Foundation has announced the initiation of new research to develop the first validated animal model of Coats' Disease, a rare eye disorder that primarily affects children.

Patient enrollment is complete in a phase 3 registrational, or pivotal, trial to evaluate OPGx-LCA5, a gene therapy that is under investigation for treating Leber congenital amaurosis type 5-associated inherited retinal disease.

An investigational treatment for vision loss associated with Bardet-Biedl syndrome is being tested in the first three patients treated.

This article discusses the current treatments being investigated during the first half of 2026.

An investigational drug has shown positive activity against metastatic uveal melanoma in a phase 1 study.

The phase 2 Early Vitrectomy and Intravitreal Antibiotics for Post-Operative Exogenous Endophthalmitis study showed that performing early vitrectomy for acute endophthalmitis can offer better and faster visual outcomes than the current treatment of prescribing antibiotics first.

A study of YB-101, a potential treatment for both Graves' disease and thyroid eye disease, has begun dosing the first patients. The molecule receive Fast Track Designation from the FDA.

Intravitreal injection of 2% hydroxypropylmethylcellulose (HPMC) dispersive viscoelastic (Eyefill HD; Bausch+Lomb) improved vision and restored ocular anatomy in eyes with structural hypotony that had visual potential.

Danon disease is a rare, multisystem X-linked genetic disorder caused by variants in the LAMP2 gene. In children and young adults, it is defined overwhelmingly by its cardiac effects . What is far less appreciated is that the eye is frequently involved and that the retinal findings can appear before the systemic diagnosis is established.

PRIMA, the first brain-computer interface approved for form vision restoration (reading letters, numbers, words) in patients with geographic atrophy (GA) secondary to age-related macular degeneration, is commercially available in Europe.

Inflammasome Therapeutics announced positive phase 2 results achieved by kamuvudine-8 (K8), its investigational drug, for geographic atrophy (GA) and a good safety signal over the 6-month period of evaluation. The company also reported significantly slower GA progression and a visual acuity advantage.